<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Longevity Drug Cycling on Longetivities</title><link>https://longetivities.com/tags/longevity-drug-cycling/</link><description>Recent content in Longevity Drug Cycling on Longetivities</description><generator>Hugo</generator><language>en-us</language><lastBuildDate>Thu, 16 Apr 2026 00:00:00 +0000</lastBuildDate><atom:link href="https://longetivities.com/tags/longevity-drug-cycling/feed.xml" rel="self" type="application/rss+xml"/><item><title>Bryan Johnson, Rapamycin, and the Blueprint Protocol: mTOR, Biological Age, and T Cells</title><link>https://longetivities.com/blog/bryan-johnson-rapamycin-and-the-blueprint-protocol-mtor-biological-age-and-t-cel/</link><pubDate>Sat, 21 Mar 2026 00:00:00 +0000</pubDate><guid>https://longetivities.com/blog/bryan-johnson-rapamycin-and-the-blueprint-protocol-mtor-biological-age-and-t-cel/</guid><description>&lt;blockquote&gt;
&lt;p&gt;&lt;strong&gt;Cluster context:&lt;/strong&gt; This article belongs to the &lt;strong&gt;Expert Protocol Profiles&lt;/strong&gt; cluster. For the broader overview, start with &lt;a href="https://longetivities.com/blog/longevity-protocols-2026-practical-evidence-guided-roadmap/"&gt;Longevity Protocols 2026: Practical, Evidence-Guided Roadmap&lt;/a&gt;.&lt;/p&gt;
&lt;/blockquote&gt;
&lt;p&gt;Bryan Johnson&amp;rsquo;s innovative and data-driven health protocol has made him one of the most watched figures in longevity research. His personal commitment to tracking biomarkers and developing the Blueprint protocol—including the decision to incorporate rapamycin and later remove it—offers valuable lessons for anyone interested in anti aging therapies.&lt;/p&gt;</description></item></channel></rss>